



2009, Vol. 16, No. 4, pp. 379–385
Copyright © 2009 Via Medica
ISSN 1897–5593
Hypertension in the very elderly:
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Abstract
This brief review discusses pharmacological management of hypertension in very elderly pa-
tients, a very powerful and rapidly growing subpopulation of patients.
It is well known that age is the most powerful risk factor for death, cardiovascular death and
hypertension. Blood pressure reduction is effective in preventing major vascular events includ-
ing stroke and heart failure. However, earlier trials were inconclusive as to whether treatment
of this age group is beneficial. One of these trials, subgroup meta-analysis (1999) which
enrolled 1,670 patients in seven clinical trials, showed a 36% lower risk of stroke and a 39%
lower risk of heart failure, but slightly increased all-cause mortality.
More recently, however, data coming from the Hypertension In the Very Elderly Trial (HYVET)
has resolved the clinical uncertainty about the relative benefits and risks of antihypertensive
treatment in patients over 80 years old. HYVET studied a relatively healthy 3,845 patients,
who were assigned to indapamide ± perindopril vs. placebo ± placebo. There was a signifi-
cant reduction in cardiovascular morbidity and mortality. What was unexpected was that
overall mortality reduced as well in actively treated individuals.
No specific guidelines exist for hypertension management for this particular population. Data
from clinical trials including HYVET favor thiazide diuretics, angiotensin converting enzyme
inhibitors and calcium channel blockers for either mono-therapy or combination therapy for
hypertension in the elderly. (Cardiol J 2009; 16, 4: 379–385)
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Introduction
According to the World Health Organization,
hypertension is the commonest cause of preventa-
ble death in developed countries and is increasin-
gly significant in developing countries [1]. The prev-
alence of hypertension increases with age. Based
on US Census Bureau data, the numbers of very
elderly people (those aged 80 or older) is expected
to reach 15 million, or 4.5% of the US population,
within the next 20 years [1, 2].
Age is the most powerful risk factor for hyper-
tension, death, and cardiovascular death [1]. Blood
pressure reduction has been shown to be effective
in preventing major vascular events including
stroke and heart failure in hypertensive individu-
als [3]. However, it has remained unclear whether
treatment of hypertension in the very elderly is
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beneficial [4, 5]. Early clinical trials enrolled few
individuals aged 85 or older. The most likely rea-
son for this was concern about their short life ex-
pectancy [6, 7]. The Seventh Report of the Joint
National Committee on Prevention, Detection,
Evaluation and Treatment of High Blood Pressure
(JNC 7) made no exceptions to the target blood
pressure recommendations in the very elderly
group of individuals [8] (Table 1).
The patterns of blood pressure elevation
change with age. Systolic blood pressure initially
rises in adolescence and continues throughout life,
while diastolic blood pressure initially increases,
then begins to decrease after the age of 60. This
leads to a widening of the pulse pressure, which is
indicative of central arterial stiffening. However, in
people who develop isolated systolic hypertension,
there is no antecedent diastolic hypertension.
These distinct patterns suggest different etiologic
and hemodynamic mechanisms for these two enti-
ties [9]. Hypertension left untreated accelerates the
development of arterial stiffness, regardless of sub-
type. This, in turn, accentuates age-related arterial
stiffening.
In patients with sustained hypertension, there
is no change in cardiac output or blood flow to the
organs due to autoregulation despite an increase in
vascular resistance. Autoregulation is maintained
both by short-term mechanisms (myogenic re-
sponse and metabolic control) and long-term mecha-
nisms (thickening of vessels and reduction in the
number of capillaries). Increases in blood pressure
lead to an activation of autoregulatory responses,
resulting in increased oxygen delivery to tissues,
decreased concentration of active metabolites, in-
creased myogenic constriction, and decreased re-
lease of endothelial vasodilatory factors.
Clinical trials
The commonest form of hypertension in eld-
erly people is isolated systolic hypertension. In the
Framingham Heart Study, 90% of participants with
normal blood pressure at the age of 55 developed
hypertension as they aged. It was found that 57%
of men and 65% of women between 65 and 89 years
developed systolic hypertension [1, 10]. Most iso-
lated systolic hypertension is caused by decreased
elasticity and increased stiffness of large arteries
as a consequence of arteriosclerosis. In addition,
elevations in blood pressure cause direct damage
to the endothelium and impaired vasodilatation.
Systolic hypertension has been identified as a risk
factor for cardiovascular and renal disease [11].
The importance of isolated systolic hyperten-
sion and its treatment has been addressed in se-
veral clinical trials (Table 2). Systolic Hypertension
in the Elderly Program (SHEP) included 4,736 in-
dividuals over the age of 65 with identified hyper-
tension. The patients were assigned to treatment
with chlorthalidone or a placebo. Chlorthalidone
therapy decreased the risk of stroke of any kind by
36%, cardiovascular risk by 25% and risk of heart
failure by 49% compared to the placebo. Further-
more, the effect of treating blood pressure to a goal
of 150 mm Hg was superior to that of aiming for
a goal of lower than 160 mm Hg [12]. The results
of the SHEP trial were supported by similar results
from two large clinical trials: European Trial in
Systolic Hypertension (Syst-Euro Trial) and Systo-
lic Hypertension in China (Syst-China Trial). In
these, treatment with nitrendipine, a calcium chan-
nel blocker, was associated with a significantly re-
duced incidence of stroke, coronary artery disease
and congestive heart failure [10, 13, 14]. A meta-
analysis of eight clinical trials involving 15,693 eld-
erly patients with isolated systolic hypertension
showed that antihypertensive therapy reduced the
risk of stroke by 30%, coronary artery disease by
23%, and cardiovascular risk by 26%. All-cause
mortality was reduced by 13% and cardiovascular
mortality by 18% [10, 15].
A recent retrospective cohort analysis by Oates
et al. [16] involved 4,071 patients, of whom 84.5%
Table 1. Cardiovascular risk factors and end-
-organ damage in hypertension (based on the
Seventh Report of the Joint Committee on
Prevention, Detection, Evaluation and Treatment
of High Blood Pressure — the JNC 7 Report).





Sedentary lifestyle Chronic kidney disease





Family history of CAD:
Men: below 55
Women: below 65
CAD — coronary artery disease; LVH — left ventricular hypertrophy;
CHF — congestive heart failure; TIA — transient ischemic attack
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were receiving blood pressure lowering agents. It
showed a shorter survival in patients with systolic
blood pressure lower than 140 mm Hg. A subgroup
meta-analysis by Gueyffier et al. [17] (INDANA sub-
group) enrolled 1,670 patients in seven clinical trials
that compared active drug therapy versus a place-
bo or no treatment. Active drug therapy showed
a 36% risk reduction of stroke, 39% reduction in
heart failure and a 22% reduction in major cardio-
vascular events. On the other hand, results showed
a 14% increase in risk of death from any cause. The
risk of cardiovascular death was shown to be slightly
higher as well. The treatment regimens used in tri-
als involved in INDANA were based on high doses
of diuretics and beta-blockers.
The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT)
was a large randomized control trial that proved that
Table 2. Summary of clinical trials involving elderly population of patients; N = number of individuals
involved in the study.
Trial Population Intervention Results
SHEP N = 4376; Chlorthalidone vs. Stroke risk reduction
age: above 65 placebo (–36%, CI 18–50; p = 0.001)
Cardiovascular risk reduction (–34%)
Heart failure risk reduction
All cause mortality reduction (–13%)
SYST-EUR N = 4695;
age: above 60 Nitrendipine ± enalapril/ Stroke risk reduction
/hydrochlorothiazide (–42%, CI –60 to –18; p = 0.002)
vs. placebo   Cardiovascular risk reduction
(–26%, CI –43 to –2; p = 0.03)
Cardiovascular mortality reduction
(–27%, CI –46 to –3; p = 0.07)
STOP- N = 6614; *BB/diuretic vs. lisinopril/ Cardiovascular mortality similar
HYPERTENSION age: above 70 /enalapril vs. felodipine/ in all three groups
/isradipine  Heart failure risk reduction similar
in all three groups
Stroke risk reduction (all types):
ACEI and CCB superior vs. BB/diuretic
(–25%, CI 0.58–0.97; p = 0.027)
ALLHAT N = 33  357; Chlorthalidone vs. Heart failure prevention: chlorthalidone
age: above 55 amlodipine/lisinopril superior vs. amlodipine/lisinopril
N = 19 013; (7.7% vs. 10.2%/8.7%)
age: above 65   Diuretic/CCB
(RR 1.38, CI 1.25–1.52, p = 0.001)
Diuretic/ACEI
(RR 1.19, CI 1.07–1.31, p = 0.001)
Stroke risk reduction: chlorthalidone
superior vs. lisinopril (5.6% vs. 6.3%;
RR 1.15, CI 1.02–1.3, p = 0.02)
Cardiovascular risk: chlorthalidone
superior vs. lisinopril (30.9% vs. 33.3%;
RR 1.10, CI 1.05–1.16, p = 0.001)
HYVET N = 3845; Indapamide ± perindopril Stroke risk reduction
age: above 80 vs. placebo  (–30%, CI –1 to 51, p = 0.05)
All cause mortality reduction
(–21%, CI 4–35, p = 0.02)
Cardiovascular mortality reduction
(–23%, CI –1 to 40, p = 0.06)
Cardiovascular risk reduction
(–34%, CI 18–47, p = 0.001)
Heart failure risk reduction
(–64%, CI 42–78, p = 0.001)
*BB/diuretic: atenolol, metoprolol, pindolol/hydrochlorothiazide + amiloride; **95% confidence interval (CI); BB — beta-blocker; ACEI — angiotensin-
-converting enzyme inhibitors; CCB — calcium channel blocker; SHEP — Systolic Hypertension in the Elderly Program; SYST-EURO — European Trial
in Systolic Hypertension; STOP-HYPERTENSION — the Swedish Trial in Old Patients with Hypertension; ALLHAT — the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial; HYVET — the Hypertension In the Very Elderly Trial
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one of the benefits of blood pressure lowering ther-
apy is the prevention of heart failure. These find-
ings were extended to the subgroup of elderly pa-
tients [18, 19]. ALLHAT compared the effects of
chlorthalidone, amlodipine and lisinopril in the pre-
vention of heart failure. Chlorthalidone was found
to be superior to amlodipine and lisinopril in heart
failure prevention. Chlorthalidone was also shown
to be more effective than lisinopril in lowering blood
pressure, preventing stroke, and decreasing com-
bined cardiovascular events. ALLHAT demonstrat-
ed that chlorthalidone had a significantly higher risk
of hyperglycemia compared with amlodipine or lisi-
nopril. Despite the higher incidence of hyperglyc-
emia, the cardiovascular risk at the long-term fol-
low-up favored chlorthalidone. Chlorthalidone re-
mained the best medication for treatment in diabetic
patients for the combined endpoints of heart fail-
ure and cardiovascular events [18].
To date, the most encouraging data supporting
aggressive management of hypertension in the eld-
erly population comes from the Hypertension In the
Very Elderly Trial (HYVET). The goal of HYVET
was to resolve the clinical uncertainty of antihyper-
tensive treatment in patients over 80 [20]. It was
designed as a randomized, double-blind placebo trial
that enrolled 3,845 patients from 195 centers in
Europe, China, Australia, and North Africa. The
patients were assigned to receive treatment with
either indapamid or a placebo. The patients who did
not achieve a blood pressure goal of 150/80 mm Hg
were then assigned perindopril or a placebo. The
primary endpoint was stroke of any kind. Second-
ary endpoints were death from any cause, death
from cardiovascular causes, death from cardiac
causes, and death from stroke. The median dura-
tion of the follow-up was 1.8 years. Results showed
a 30% reduction in stroke rate. The rate of fatal
stroke was reduced by 39%. With regard to second-
ary endpoints, there was a 21% reduction in the rate
of death from any cause, the rate of death from car-
diovascular causes was reduced by 23%, but the rate
of death from cardiac causes was not reduced sig-
nificantly in the actively treated group. There was
a significant reduction of the rate of fatal or non-
fatal heart failure (64%), and the rate of any cardio-
vascular event (death from cardiovascular events
or stroke, myocardial infarction, heart failure, 34%)
[20].
There were no significant differences in serum
potassium levels between the groups as well as in
serum glucose, creatinine or uric acid. The number
of serious events was lower in the actively treated
group [20].
The significant reduction in the risk of heart
failure demonstrated in HYVET strongly supports
the ALLHAT conclusions. The lowest rates of fa-
tal events and hospitalizations for heart failure were
found in patients treated with diuretic or angio-
tensin converting enzyme inhibitors (ACEI). Heart
failure remains the most frequent reason for hos-
pital admissions among patients over 65 in the United
States, with the one-year mortality rate ranging
from 20 to 50%. Hypertension remains one of the
most powerful risk factors for heart failure. ALLHAT
and HYVET results stress the importance of blood
pressure control in preventing heart failure.
The data from HYVET, which demonstrates
risk reduction in death from any cause in the active-
ly treated group, outweighs the results of INDANA
meta-analysis. The blood pressure regimen used in
the studies involved in INDANA consisted of high
doses of diuretics and beta-blockers. Diuretics used
as a single drug are associated with high risk of
hypokalemia and related arrhythmias. A combina-
tion of diuretic and ACEI may have a balanced ef-
fect on serum potassium levels [20].
Data from the Anglo-Scandinavian Cardiac
Outcomes Trial-Blood Pressure Lowering Arm
(ASCOT-BPLA) showed beta-blockers to be less
effective in the treatment of hypertension [21].
These observations may partially explain the unfa-
vorable results of the INDANA meta-analysis.
HYVET and the Swedish Trial in Old Patients
with Hypertension (STOP-Hypertension) trial both
demonstrated the mortality benefit of blood pres-
sure management [22, 23].
Discussion
A therapeutic approach to the management of
hypertension in the very elderly should start with
lifestyle modifications. This remains the case re-
gardless of age. Lifestyle modifications include
weight reduction, dietary modifications (i.e. reduc-
tion of salt intake and increases in fruit and vegeta-
ble intake), increase in physical activity and mo-
derate alcohol consumption. Clinical trials have
identified five classes of medication that have been
successfully used in elderly patients. These clas-
ses are: thiazide diuretics, ACEI, beta-blockers, an-
giotesin-receptor antagonists and calcium channel
blockers.
Joint National Committee 7 guidelines recom-
mend thiazide-type diuretics as initial drug therapy
for most patients with hypertension, regardless of
age (Table 3). Thiazides can be administered once
daily and are efficient in low doses in the elderly.
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Additionally, they can be successfully combined
with other classes of anti-hypertensive medications
with additive effects and minimal side effects.
Known side effects of diuretics include hypokale-
mia, hyperglycemia, hypomagnesaemia and hyper-
uricemia. None of these side effects has been asso-
ciated with increased short-term mortality in clini-
cal trials [9].
Certain classes of antihypertensive medication
are indicated if significant medical conditions coex-
ist, e.g. hypertension with coexisting chronic kid-
ney insufficiency is an indication for ACEI or angio-
tensin-receptor blocker; a history of myocardial
infarction is an indication for beta-blockers. The
American College of Cardiology and the American
Heart Association recommend ACEI as first-line
agents in all stages of heart failure. ACEI improve
exercise tolerance and reduce death from heart fail-
ure in all patients, including elderly patients. The
mechanism of action is based on decreasing produc-
tion of angiotensin II and reducing sympathetic
nervous system activity. The sympatholytic actions
in heart failure increase the ventricular filling time
and improve contractile efficiency. The most com-
mon side effects of ACEI are: cough, hyperkalem-
ia, angioedema and reversible functional renal in-
sufficiency secondary to reduced renal perfusion
pressure.
The benefits of beta-blockers therapy for eld-
erly patients with hypertension have been ques-
tioned recently [10]. A meta-analysis of interven-
tion trials for hypertension showed a 16% higher
incidence of stroke among patients treated with
beta-blockers (primarily atenolol) compared to
those treated with other antihypertensive medica-
tions [24]. The lack of benefit from beta-blockers
could be attributed to a smaller reduction in blood
pressure compared with other medication classes.
The most important mechanisms responsible for
antihypertensive beta-blockers include: inhibition
of renin release, central nervous system effect, re-
duction of heart rate and cardiac output, reduction
in peripheral vascular resistance, and reduction in
vasomotor tone. Beta-blockers may worsen glucose
intolerance or mask the symptoms of hypoglycemia
and should be used with caution in patients with
insulin-dependant diabetes mellitus. Elderly pa-
tients are at high risk of developing orthostatic hy-
potension with beta-blockers. Beta-blockers are
most appropriate for the management of hyperten-
sion accompanied by ischemic heart disease, heart
failure and arrhythmias and their use in elderly pa-
tients should probably be limited to those with these
pre-existing conditions. It is unclear whether such
restrictions should also apply to newer beta-block-
ers with peripheral vasodilator effects.
The main differences between the treatment
of older as opposed to younger individuals are
careful monitoring of elderly patients towards
postural and postprandial hypotension before in-
itiation of treatment. Elderly patients may have
sluggish baroreceptors and sympathetic nervous
responsiveness as well as impaired cerebral au-
toregulation. Thus the reduction of blood pressure
Table 3. Existing guidelines for general population of patients.
Guidelines Area of concern Target BB [mm Hg] Drug of choice
JNC 7 General population < 140/80 Thiazide diuretic# unless other
medical conditions preexist
DM, CKD < 130/80 ACEI or ARB
AHA and General population/ < 140/80 Any group
ESH/ESC /primary CAD prevention
High CAD risk* < 130/80 ACEI or ARB or CCB or
thiazide diuretic or combination
Stable angina < 130/80 BB and ACEI or ARB
ACS** < 130/80 BB and ACEI or ARB
Left ventricular < 120/80 ACEI or ARB and BB and
dysfunction aldosterone antagonist and
thiazide diuretic or loop diuretic and
hydralazine/isosorbide dinitrate
#without compelling indication: heart failure, post-myocardial infarction, CKD, DM etc. (see text); *DM, CKD, known coronary artery disease (CAD) or
CAD equivalent (carotid artery disease, peripheral arterial disease, abdominal aortic aneurysm) or 10-year Framingham risk score ≥ 10%; **unstable
angina, STEMI, NSTEMI; JNC7 — the Seventh Report of the Joint Committee on Prevention, Detection, Evaluation and Treatment of High Blood
Pressure; ESH — European Society of Hypertension; ESC — European Society of Cardiology; ACS — acute coronary syndrome; ACEI — angioten-
sin-converting enzyme inhibitors; ARB — angiotensin receptor blockers; BB — beta-blocker; CCB — calcium channel blocker; DM — diabetes melli-
tus; CKD — chronic kidney disease
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Table 4. General guidelines for treatment of hypertension in the very elderly (age above 80).
Blood pressure goal [mm Hg] Drug of choice Special precautions
General population: Thiazide diuretic and/or Dose: carefully, use low
< 140/80 ACEI, and CCB in combination initial doses to minimize
High CAD risk: < 130/80  to reach target blood pressure side effects
Left ventricular dysfunction:  Avoid beta-blocker as primary therapy Assess for postural/
< 120/80  unless specific indication exists /postprandial hypotension
(e.g. status post MI, CHF) before initiating therapy
Note that trials involved
relatively fit and active
individuals, apply carefully
to frail patients
ACEI— angiotensin-converting enzyme inhibitors; CAD — coronary artery disease; CCB — calcium channel blocker; CHF — congestive heart failure;
MI — myocardial infarction;
should be gradual to minimize the risk, and these
patients may require lower initial doses of medica-
tion. We also emphasize that trials showing bene-
fits from the treatment of hypertension in the eld-
erly were performed in relatively fit patients. Great-
er caution should be applied to the therapy of frail
individuals.
Treatment of hypertension in the elderly
shows a significant benefit, regardless of the med-
ication group (Table 4). All the guidelines (The Joint
National Committee, American Medical Associa-
tion, American Heart Association, American Soci-
ety of Hypertension, European Society for Hyper-
tension, and European Society of Cardiology) em-
phasize that the major benefits of therapy are
related to lowering blood pressure and controlling
hypertension [25]. Thiazide diuretics and ACEI
seem to be optimal drugs to safely achieve blood
pressure reduction and may provide survival bene-
fits and reduce the risk of stroke or heart failure
[20]. Calcium channel blockers can be sequentially
added or substituted. Data suggests that beta-block-
ers should not be used as primary therapy for hy-
pertension in the elderly. They do not appear to be
better than other groups in primary prevention of
myocardial infarction in this population, and may be
less effective in stroke prevention than other
agents. Unless indicated (post-myocardial infarction
or coronary heart failure) beta-blockers should be
avoided in very elderly patients.
Summary
Existing data, specifically the HYVET trial re-
sults, indicates an overall benefit of hypertension
treatment in the very elderly. Treatment of hyper-
tension is likely to prevent heart failure, reduce
stroke and prolong life. The target blood pressure
in the very elderly needs to be further established,
but based on the HYVET trial, a blood pressure tar-
get of less than 150/80 mm Hg seems both effec-
tive and safe [20]. More aggressive goals, such as
those of the JNC-7, may be similarly appropriate for
the very elderly.
Current evidence favors the use of diuretics
(indapamide or chlorthalidone) as the initial drugs
used in the management of hypertension in this
subpopulation. However, as shown in ALLHAT and
HYVET, single drug therapy may not be sufficient-
ly effective to achieve target blood pressure goals
and ACEI would be a reasonable option for combi-
nation therapy [1, 18].
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